community-acquired pneumonia

Community-acquired pneumonia (CAP) is the 4-8th leading killer of people worldwide and the most leading cause of death from infections in US. This article is a review of innovations and differences between the recent American Thoracic Society (ATS) …

Validation of the following assessment tools (APACHEII, SOFA, CURB-65, CRB-65, PORT, SMRT-CO) was performed based on data obtained from 300 ICU patients with community-acquired pneumonia (CAP). Predictive value of the scores was determined using …

Efficacy of regional standard of care «CommunityAcquired Pneumonia» and Sverdlovsk regional healthcare program «Intensive Care» were assessed. This paper presents results of retrospective analysis of ICU hospitalizations for severe community-acquired …

Gemifloxacin is a new respiratory fluoroquinolone that was approved as Factive® in Russian Federation in December 2005. Among the fluoroquinolones this agent is the most active against Streptococcus pneumoniae, and has similar to other respiratory …

These guidelines are a result of consensus expert opinion based on peer review of the literature published over the last 10 years. References include a number of international guidelines for the management of adults in community-acquired pneumonia …

Сommunity-acquired pneumonia remains one of the most common infections in population, and despite the wide array of antimicrobials, it is associated with high lethality rate. First 24-hours mortality is an integral characteristic of the quality of …

Case histories of outpatients with community-acquired pneumonia (CAP) who had not required hospitalization were randomly selected in seven regions of Russia for retrospective analysis. Diagnoses were classified according to the ICD-10; antimicrobials …